Biocept Inc (NASDAQ:BIOC), a liquid biopsy provider, announced Monday that a peer-review journal published validation results showing the high sensitivity of its Target Selector testing for EGFR, BRAF and KRAS mutations in plasma circulating tumor DNA (ctDNA).
The company said the article was published in the journal PLOS ONE this month and will also be included as part of a special collection of topical articles entitled Targeted Anticancer Therapies And Precision Medicine In Cancer.
In a statement, Biocept said Target Selector testing for EGFR, BRAF, and KRAS mutations has been validated to an ultra-sensitive single copy level, with a limit of detection (LOD) of 0.02% or better.
READ: Biocept wins South Korea patent for its Switch-Block technology used to detect rare cancer mutations
The San Diego-based company’s biomarker tests provide coverage for the most common actionable mutations associated with clinical guidelines for targeted cancer therapy.
Target Selector tests performed in Biocept's laboratory provide a commercial turnaround time of 3-4 days, and offer a cost-effective strategy to guide treatment decisions and monitor therapeutic response. At the core of Target Selector is the company’s Switch-Blocker technology, used in detecting rare cancers associated with mutations.
"Biocept's patented Switch-Blocker technology uniquely amplifies mutations of interest from the blood of patients with cancer, while blocking wild type DNA. This enables very high sensitivity and detection down to a single gene copy," said Jason Poole, Biocept's vice president of research and development and the study's lead author.
"We are very pleased to have this analytical validation published in PLOS ONE, and believe the results demonstrate the high sensitivity and performance of our novel liquid biopsy assays, which are designed to provide oncologists with the information they need to select the right targeted therapy for their patients."
CEO Michael Nall noted that Target Selector liquid biopsies “continues to emerge as an important tool to cost-effectively qualify patients for therapy and, importantly, monitor therapeutic response and disease progression for physicians and their patients with cancer."
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham